Aaron  Cox net worth and biography

Aaron Cox Biography and Net Worth

Aaron Cox joined Horizon in 2016 and has served in various roles across finance, business development and corporate development, including as executive vice president, finance; chief of staff for the chairman, president and chief executive officer; and senior vice president, corporate development, where he had responsibilities spanning financial planning, corporate strategy, mergers and acquisitions (M&A), acquisition integration, capital markets planning, real estate, security and investor relations. Cox also previously spent time on Horizon’s business development team, where he supported multiple acquisitions, financings and licensing transactions.

Before joining Horizon, Cox was vice president, capital markets at BMO Capital Markets, where he advised clients on debt financing transactions across various levels of the capital structure. Before BMO, he held investment banking roles at JMP Securities and Stout, where he provided advisory services, including for capital raising and M&A activities, to companies across a wide range of sectors.

Cox earned a Master of Business Administration from the University of Chicago and a Bachelor of Business Administration in finance from the University of Notre Dame.

What is Aaron Cox's net worth?

The estimated net worth of Aaron Cox is at least $32,215.10 as of January 13th, 2023. Mr. Cox owns 277 shares of Horizon Therapeutics Public stock worth more than $32,215 as of November 15th. This net worth approximation does not reflect any other investments that Mr. Cox may own. Additionally, Mr. Cox receives an annual salary of $1,360,000.00 as CFO at Horizon Therapeutics Public. Learn More about Aaron Cox's net worth.

How old is Aaron Cox?

Mr. Cox is currently 40 years old. There are 6 older executives and no younger executives at Horizon Therapeutics Public. The oldest executive at Horizon Therapeutics Public is Mr. Timothy P. Walbert, Chairman, Pres & CEO, who is 56 years old. Learn More on Aaron Cox's age.

What is Aaron Cox's salary?

As the CFO of Horizon Therapeutics Public Limited, Mr. Cox earns $1,360,000.00 per year. There are 4 executives that earn more than Mr. Cox. The highest earning executive at Horizon Therapeutics Public is Mr. Sean M. Clayton J.D., Exec. VP & Gen. Counsel, who commands a salary of $7,030,000.00 per year. Learn More on Aaron Cox's salary.

How do I contact Aaron Cox?

The corporate mailing address for Mr. Cox and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Aaron Cox's contact information.

Has Aaron Cox been buying or selling shares of Horizon Therapeutics Public?

Aaron Cox has not been actively trading shares of Horizon Therapeutics Public over the course of the past ninety days. Most recently, Aaron Cox sold 36,148 shares of the business's stock in a transaction on Friday, January 13th. The shares were sold at an average price of $113.17, for a transaction totalling $4,090,869.16. Following the completion of the sale, the chief financial officer now directly owns 277 shares of the company's stock, valued at $31,348.09. Learn More on Aaron Cox's trading history.

Who are Horizon Therapeutics Public's active insiders?

Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Aaron Cox Insider Trading History at Horizon Therapeutics Public

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/13/2023Sell36,148$113.17$4,090,869.16277View SEC Filing Icon  
See Full Table

Aaron Cox Buying and Selling Activity at Horizon Therapeutics Public

This chart shows Aaron Cox's buying and selling at Horizon Therapeutics Public by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public logo
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $116.30
Low: $116.30
High: $116.30

50 Day Range

MA: $115.72
Low: $112.60
High: $116.30

2 Week Range

Now: $116.30
Low: $60.03
High: $116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03